

Roger McIntyre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9447373/publications.pdf>

Version: 2024-02-01

699
papers

43,173
citations

2426

97
h-index

4427

172
g-index

754
all docs

754
docs citations

754
times ranked

36010
citing authors

#	ARTICLE	IF	CITATIONS
1	Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment. <i>CNS Spectrums</i> , 2023, 28, 90-97.	0.7	11
2	The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia. <i>CNS Spectrums</i> , 2023, 28, 319-330.	0.7	4
3	Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine. <i>CNS Spectrums</i> , 2023, 28, 288-299.	0.7	4
4	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2023, 68, 299-311.	0.9	5
5	Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis. <i>CNS Spectrums</i> , 2022, 27, 73-81.	0.7	9
6	The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid Dataset. <i>CNS Spectrums</i> , 2022, 27, 378-382.	0.7	6
7	Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?. <i>Journal of Sleep Research</i> , 2022, 31, e13400.	1.7	11
8	Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 514-521.	2.0	10
9	Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence. <i>CNS Spectrums</i> , 2022, 27, 322-330.	0.7	5
10	Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. <i>CNS Spectrums</i> , 2022, 27, 315-321.	0.7	7
11	What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. <i>Journal of Affective Disorders</i> , 2022, 298, 565-576.	2.0	8
12	Pharmacogenomics of ketamine: A systematic review. <i>Journal of Psychiatric Research</i> , 2022, 145, 27-34.	1.5	18
13	Deficits of social cognition in bipolar disorder: Systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2022, 24, 137-148.	1.1	23
14	Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 93-135.	2.0	670
15	Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 300, 449-461.	2.0	34
16	A Systematic Review and Meta-Analysis of Symptoms of Anxiety, Depression, and Insomnia in Spain in the COVID-19 Crisis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1018.	1.2	33
17	Premenopausal Singaporean Women Suffering from Major Depressive Disorder Treated with Selective Serotonin Reuptake Inhibitors Had Similar Bone Mineral Density as Compared with Healthy Controls. <i>Diagnostics</i> , 2022, 12, 96.	1.3	2
18	Efficacy of Lycium barbarum polysaccharide in adolescents with subthreshold depression: interim analysis of a randomized controlled study. <i>Neural Regeneration Research</i> , 2022, 17, 1582.	1.6	17

#	ARTICLE	IF	CITATIONS
19	Immune response to vaccination in adults with mental disorders: A systematic review. <i>Journal of Affective Disorders</i> , 2022, 304, 66-77.	2.0	14
20	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. <i>Molecular Psychiatry</i> , 2022, 27, 1286-1299.	4.1	68
21	Early optimized pharmacological treatment in patients with depression and chronic pain. <i>CNS Spectrums</i> , 2022, , 1-12.	0.7	0
22	Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. <i>Bipolar Disorders</i> , 2022, 24, 354-374.	1.1	23
23	The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. <i>Psychopharmacology</i> , 2022, 239, 2011-2039.	1.5	19
24	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	1.3	49
25	Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. <i>Infectious Diseases</i> , 2022, 54, 467-477.	1.4	42
26	The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 841-852.	1.0	13
27	The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: A systematic review. <i>Journal of Psychiatric Research</i> , 2022, 149, 252-259.	1.5	13
28	The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. <i>Journal of Affective Disorders</i> , 2022, 304, 78-84.	2.0	6
29	Microbiome abnormalities as a possible link between diabetes mellitus and mood disorders: Pathophysiology and implications for treatment. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 137, 104640.	2.9	4
30	Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC).. <i>Innovations in Clinical Neuroscience</i> , 2022, 19, 26-32.	0.1	3
31	Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation. <i>Frontiers in Psychiatry</i> , 2022, 13, 779326.	1.3	4
32	The abuse liability of ketamine: A scoping review of preclinical and clinical studies. <i>Journal of Psychiatric Research</i> , 2022, 151, 476-496.	1.5	20
33	Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review. <i>Psychiatry Research</i> , 2022, 312, 114579.	1.7	5
34	Screening Depressive Symptoms and Incident Major Depressive Disorder Among Chinese Community Residents Using a Mobile App-Based Integrated Mental Health Care Model: Cohort Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e30907.	2.1	10
35	Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. <i>Journal of Psychiatric Research</i> , 2022, 151, 693-709.	1.5	52
36	Effects of 28 days of cannabis abstinence on cognition in major depressive disorder: A pilot study. <i>American Journal on Addictions</i> , 2022, 31, 454-462.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Evaluating cognitive function in unaffected relatives of individuals with bipolar disorders: A meta-analysis. <i>Journal of Psychiatric Research</i> , 2022, 152, 289-295.	1.5	4
38	Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110032.	2.5	6
39	Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychiatric Research</i> , 2021, 136, 444-451.	1.5	1
40	Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110126.	2.5	12
41	The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychopharmacology</i> , 2021, 35, 128-136.	2.0	11
42	The influence of prescriber and patient gender on the prescription of benzodiazepines: evidence for stereotypes and biases?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 1083-1089.	1.6	10
43	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. <i>Journal of Psychiatric Research</i> , 2021, 133, 82-92.	1.5	27
44	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommendations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Ketamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 113-125.	1.5	54
45	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2021, 134, 57-68.	1.5	58
46	Effects of infliximab on brain neurochemistry of adults with bipolar depression. <i>Journal of Affective Disorders</i> , 2021, 281, 61-66.	2.0	7
47	Cumulative Cardiovascular Disease Risk and Triglycerides Differentially Relate to Subdomains of Executive Function in Bipolar Disorder; preliminary findings. <i>Journal of Affective Disorders</i> , 2021, 278, 556-562.	2.0	10
48	Resting-State Functional Connectivity and Brain Network Abnormalities in Depressive Patients with Suicidal Ideation. <i>Brain Topography</i> , 2021, 34, 234-244.	0.8	15
49	Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. <i>Psychopharmacology</i> , 2021, 238, 917-926.	1.5	19
50	The impact of COVID-19 on subthreshold depressive symptoms: a longitudinal study. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e20.	1.8	35
51	Development of new rapid-action treatments in mood disorders. , 2021, , 139-146.		0
52	Convolutional Neural Network-Based Deep Learning Model for Predicting Differential Suicidality in Depressive Patients Using Brain Generalized q-Sampling Imaging. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	6
53	Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. <i>CNS Spectrums</i> , 2021, , 1-9.	0.7	9
54	Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls. <i>BJPsych Open</i> , 2021, 7, e55.	0.3	9

#	ARTICLE	IF	CITATIONS
55	Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 575-585.	1.0	33
56	The impact of COVID-19 pandemic on global mental health: From the general public to healthcare workers. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 198-199.	0.2	12
57	A chain mediation model on COVID-19 symptoms and mental health outcomes in Americans, Asians and Europeans. <i>Scientific Reports</i> , 2021, 11, 6481.	1.6	172
58	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. <i>Journal of Affective Disorders</i> , 2021, 282, 160-164.	2.0	24
59	Mapping Brain Microstructure and Network Alterations in Depressive Patients with Suicide Attempts Using Generalized Q-Sampling MRI. <i>Journal of Personalized Medicine</i> , 2021, 11, 174.	1.1	7
60	Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application. <i>Psychiatry Research</i> , 2021, 298, 113800.	1.7	7
61	Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021, 38, 2795-2820.	1.3	19
62	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	4.0	270
63	Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression.. <i>Journal of Affective Disorders</i> , 2021, 287, 54-68.	2.0	17
64	A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat. <i>Journal of Affective Disorders</i> , 2021, 286, 360-369.	2.0	36
65	Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight. <i>Journal of Affective Disorders</i> , 2021, 289, 167-176.	2.0	9
66	The relationship between childhood emotional abuse and depressive symptoms among Chinese college students: The multiple mediating effects of emotional and behavioral problems. <i>Journal of Affective Disorders</i> , 2021, 288, 129-135.	2.0	14
67	Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. <i>Journal of Affective Disorders</i> , 2021, 288, 210-216.	2.0	6
68	Clinical laboratory tests and five-year incidence of major depressive disorder: a prospective cohort study of 433,890 participants from the UK Biobank. <i>Translational Psychiatry</i> , 2021, 11, 380.	2.4	12
69	The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence. <i>Psychiatry Research</i> , 2021, 300, 113860.	1.7	3
70	Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death. <i>JAMA Psychiatry</i> , 2021, 78, 1079.	6.0	151
71	Inflammation and disease modification in bipolar disorders: Priority avenues for future research. <i>Bipolar Disorders</i> , 2021, 23, 442-444.	1.1	2
72	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. <i>Journal of Affective Disorders</i> , 2021, 290, 364-377.	2.0	159

#	ARTICLE	IF	CITATIONS
73	Comparison of Brain Activation Patterns during Olfactory Stimuli between Recovered COVID-19 Patients and Healthy Controls: A Functional Near-Infrared Spectroscopy (fNIRS) Study. <i>Brain Sciences</i> , 2021, 11, 968.	1.1	37
74	Application of computerized cognitive test battery in major depressive disorder: a narrative literature review. <i>Nordic Journal of Psychiatry</i> , 2021, , 1-9.	0.7	0
75	Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. <i>CNS Drugs</i> , 2021, 35, 925-934.	2.7	35
76	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). <i>Psychiatry Research</i> , 2021, 302, 113993.	1.7	16
77	Comparison of functional dorsal attention network alterations in breast cancer survivors before and after chemotherapy. <i>Medicine (United States)</i> , 2021, 100, e27018.	0.4	3
78	Assessment of Disrupted Brain Structural Connectome in Depressive Patients With Suicidal Ideation Using Generalized Q-Sampling MRI. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 711731.	1.0	4
79	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. <i>Journal of Affective Disorders</i> , 2021, 292, 714-719.	2.0	5
80	Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. <i>Psychiatry Research</i> , 2021, 303, 114086.	1.7	5
81	Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 899-913.	0.6	24
82	Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 473-479.	1.1	43
83	Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 144, 129-137.	1.5	214
84	Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. <i>Journal of Affective Disorders</i> , 2021, 293, 285-294.	2.0	28
85	Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot study. <i>Journal of Affective Disorders</i> , 2021, 293, 73-77.	2.0	8
86	The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. <i>Journal of Affective Disorders</i> , 2021, 294, 592-596.	2.0	10
87	Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. <i>Journal of Psychiatric Research</i> , 2021, 143, 209-214.	1.5	3
88	Management of cognitive impairment in bipolar disorder: a systematic review of randomized controlled trials. <i>CNS Spectrums</i> , 2021, , 1-22.	0.7	8
89	Classification and Visualization of Chemotherapy-Induced Cognitive Impairment in Volumetric Convolutional Neural Networks. <i>Journal of Personalized Medicine</i> , 2021, 11, 1025.	1.1	3
90	The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. <i>Journal of Psychiatric Research</i> , 2021, 144, 312-319.	1.5	9

#	ARTICLE	IF	CITATIONS
91	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. <i>Bipolar Disorders</i> , 2021, 23, 767-788.	1.1	32
92	Functional near-infrared spectroscopy during the verbal fluency task of English-Speaking adults with mood disorders: A preliminary study. <i>Journal of Clinical Neuroscience</i> , 2021, 94, 94-101.	0.8	14
93	The Relationship Between Cognitive Dysfunction Through THINC-Integrated Tool (THINC-it) and Psychosocial Function in Chinese Patients With Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2021, 12, 763603.	1.3	4
94	Frequency Analysis of Symptomatic Worsening Following Ketamine Infusions For Treatment Resistant Depression in a Real-World Sample: Results From the Canadian Rapid Treatment Centre of Excellence. <i>Psychiatry Research</i> , 2021, 307, 114321.	1.7	5
95	Social Isolation, Loneliness and Generalized Anxiety: Implications and Associations during the COVID-19 Quarantine. <i>Brain Sciences</i> , 2021, 11, 1620.	1.1	27
96	Economic, physical and social determinants of health during the COVID-19 lockdown: a call for renewed societal responses. , 2021, , 232-243.		0
97	Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: A case-control study. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 357-367.	1.3	16
98	The effect of caloric restriction on working memory in healthy non-obese adults. <i>CNS Spectrums</i> , 2020, 25, 2-8.	0.7	46
99	Are early increases in physical activity a behavioral marker for successful antidepressant treatment?. <i>Journal of Affective Disorders</i> , 2020, 260, 287-291.	2.0	4
100	Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. <i>CNS Spectrums</i> , 2020, 25, 502-510.	0.7	178
101	Inflammation, brain structure and cognition interrelations among individuals with differential risks for bipolar disorder. <i>Brain, Behavior, and Immunity</i> , 2020, 83, 192-199.	2.0	11
102	Effects of Lower Past-Year Serum Sodium and Hyponatremia on Depression Symptoms and Cognitive Impairments in Patients With Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 169-177.	0.4	12
103	Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis. <i>Journal of Medical Economics</i> , 2020, 23, 262-270.	1.0	7
104	Leptin, obesity, and response to ketamine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 98, 109773.	2.5	5
105	Parsing metabolic heterogeneity in mood disorders: A hypothesis-driven cluster analysis of glucose and insulin abnormalities. <i>Bipolar Disorders</i> , 2020, 22, 79-88.	1.1	10
106	A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. <i>Journal of Affective Disorders</i> , 2020, 263, 386-395.	2.0	18
107	Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. <i>Journal of Affective Disorders</i> , 2020, 263, 258-266.	2.0	12
108	Depression in the medically ill. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 346-366.	1.3	24

#	ARTICLE	IF	CITATIONS
109	The efficacy of mind-body (Baduanjin) exercise on self-reported sleep quality and quality of life in elderly subjects with sleep disturbances: a randomized controlled trial. <i>Sleep and Breathing</i> , 2020, 24, 695-701.	0.9	26
110	Acyl-Carnitine plasma levels and their association with metabolic syndrome in individuals with schizophrenia. <i>Psychiatry Research</i> , 2020, 293, 113458.	1.7	8
111	The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis. <i>Psychiatry Research</i> , 2020, 294, 113514.	1.7	156
112	Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization. <i>Journal of Affective Disorders</i> , 2020, 277, 30-38.	2.0	27
113	Bipolar disorders. <i>Lancet, The</i> , 2020, 396, 1841-1856.	6.3	419
114	Impact of COVID-19 pandemic on mental health in the general population: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 277, 55-64.	2.0	3,399
115	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 276, 576-584.	2.0	118
116	In vivo phenotyping, mechanism-informed treatments, domain-based psychopathology and nomological networks: A strategy for treatment discovery and development in bipolar depression. <i>Bipolar Disorders</i> , 2020, 22, 657-659.	1.1	10
117	A quantitative and qualitative study on the neuropsychiatric sequelae of acutely ill COVID-19 inpatients in isolation facilities. <i>Translational Psychiatry</i> , 2020, 10, 355.	2.4	131
118	The clinical characterization of the adult patient with depression aimed at personalization of management. <i>World Psychiatry</i> , 2020, 19, 269-293.	4.8	174
119	The Association Between Physical and Mental Health and Face Mask Use During the COVID-19 Pandemic: A Comparison of Two Countries With Different Views and Practices. <i>Frontiers in Psychiatry</i> , 2020, 11, 569981.	1.3	254
120	The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary. <i>Bipolar Disorders</i> , 2020, 22, 788-804.	1.1	61
121	The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. <i>Bipolar Disorders</i> , 2020, 22, 805-821.	1.1	87
122	Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. <i>Bipolar Disorders</i> , 2020, 22, 440-460.	1.1	66
123	The Association between Selective Serotonin Reuptake Inhibitors (SSRIs) Use and the Risk of Bladder Cancer: A Nationwide Population-Based Cohort Study. <i>Cancers</i> , 2020, 12, 1184.	1.7	12
124	Preventing suicide in the context of the COVID-19 pandemic. <i>World Psychiatry</i> , 2020, 19, 250-251.	4.8	145
125	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. <i>Bipolar Disorders</i> , 2020, 22, 831-840.	1.1	40
126	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020, 274, 903-910.	2.0	70

#	ARTICLE	IF	CITATIONS
127	Caloric restriction, resting metabolic rate and cognitive performance in Non-obese adults: A post-hoc analysis from CALERIE study. <i>Journal of Psychiatric Research</i> , 2020, 128, 16-22.	1.5	15
128	Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1031-1040.	1.0	25
129	PSYCHOMETRIC properties of the Chinese version of the THINC-it tool for cognitive symptoms in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 273, 586-591.	2.0	11
130	Effect of body anthropometrics on brain structure of offspring of parents with bipolar disorder. <i>Journal of Psychiatric Research</i> , 2020, 124, 137-142.	1.5	1
131	Modeling the Research Landscapes of Artificial Intelligence Applications in Diabetes (GAPRESEARCH). <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1982.	1.2	11
132	Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update—Reader Comment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 213-215.	0.6	0
133	The Mental Health Effects of COVID-19 on Health Care Providers in China. <i>American Journal of Psychiatry</i> , 2020, 177, 635-636.	4.0	76
134	Synergistic effect of social media use and psychological distress on depression in China during the COVID-19 epidemic. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 552-554.	1.0	22
135	The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change. <i>Frontiers in Psychiatry</i> , 2020, 11, 546.	1.3	17
136	Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression. <i>Psychoneuroendocrinology</i> , 2020, 120, 104779.	1.3	11
137	Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 100-106.	2.0	773
138	Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders. <i>Psychiatry Research</i> , 2020, 288, 112967.	1.7	6
139	Current and Future Vistas in Bipolar Disorder. <i>Current Behavioral Neuroscience Reports</i> , 2020, 7, 68-75.	0.6	0
140	A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 40-48.	2.0	1,880
141	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. <i>Journal of Affective Disorders</i> , 2020, 272, 1-7.	2.0	28
142	Is returning to work during the COVID-19 pandemic stressful? A study on immediate mental health status and psychoneuroimmunity prevention measures of Chinese workforce. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 84-92.	2.0	461
143	Association of alkali metals and Alkaline-earth metals with the risk of schizophrenia in a Chinese population: A Case-Control study. <i>Journal of Trace Elements in Medicine and Biology</i> , 2020, 60, 126478.	1.5	6
144	Registered clinical trials investigating ketamine for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2020, 127, 1-12.	1.5	22

#	ARTICLE	IF	CITATIONS
145	What is bipolar disorder? A disease model of dysregulated energy expenditure. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 113, 529-545.	2.9	15
146	Mental, emotional, and behavioral effects of ketogenic diet for non-epileptic neuropsychiatric conditions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 102, 109947.	2.5	14
147	Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. <i>Cells</i> , 2020, 9, 895.	1.8	36
148	Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2020, 11, 621773.	1.3	74
149	Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder. <i>Psychiatry Research</i> , 2020, 284, 112767.	1.7	2
150	Projected increases in suicide in Canada as a consequence of COVID-19. <i>Psychiatry Research</i> , 2020, 290, 113104.	1.7	149
151	Mental health conditions among the general population, healthcare workers and quarantined population during the coronavirus disease 2019 (COVID-19) pandemic. <i>Psychology, Health and Medicine</i> , 2020, , 1-13.	1.3	19
152	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020, 98, 683-697H.	1.5	25
153	A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	13
154	Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. primary care companion for CNS disorders, <i>The</i> , 2020, 22, .	0.2	11
155	Drs Rosenblat and McIntyre Reply. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	1
156	Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 37-45.	1.0	17
157	Peripheral interleukin-6 levels and working memory in non-obese adults: A post-hoc analysis from the CALERIE study. <i>Nutrition</i> , 2019, 58, 18-22.	1.1	8
158	Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease. <i>Behavioural Brain Research</i> , 2019, 356, 271-278.	1.2	67
159	Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 777-783.	1.4	6
160	Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. <i>Current Medical Research and Opinion</i> , 2019, 35, 2169-2177.	0.9	8
161	Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. <i>Current Medical Research and Opinion</i> , 2019, 35, 1993-2005.	0.9	81
162	Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. <i>Journal of Affective Disorders</i> , 2019, 257, 600-606.	2.0	22

#	ARTICLE	IF	CITATIONS
163	Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109720.	2.5	35
164	Keeping up with the clinical advances: depression. <i>CNS Spectrums</i> , 2019, 24, 25-37.	0.7	18
165	Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force. <i>Bipolar Disorders</i> , 2019, 21, 582-594.	1.1	74
166	Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. <i>Bipolar Disorders</i> , 2019, 21, 686-719.	1.1	69
167	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>International Journal of Bipolar Disorders</i> , 2019, 7, 8.	0.8	39
168	Machine learning and big data: Implications for disease modeling and therapeutic discovery in psychiatry. <i>Artificial Intelligence in Medicine</i> , 2019, 99, 101704.	3.8	100
169	Antidepressants Reduced Risk of Mortality in Patients With Diabetes Mellitus: A Population-Based Cohort Study in Taiwan. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4619-4625.	1.8	8
170	Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. <i>Comprehensive Psychiatry</i> , 2019, 94, 152113.	1.5	33
171	Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 1388-1394.	2.0	14
172	Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. <i>Experimental Neurology</i> , 2019, 315, 1-8.	2.0	82
173	The International Consortium Investigating Neurocognition in Bipolar Disorder (ICONIC â€•BD). <i>Bipolar Disorders</i> , 2019, 21, 6-10.	1.1	12
174	Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. <i>Translational Psychiatry</i> , 2019, 9, 19.	2.4	44
175	The Current Research Landscape on the Artificial Intelligence Application in the Management of Depressive Disorders: A Bibliometric Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2150.	1.2	53
176	Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2255.	1.2	30
177	Effort-based decision-making is affected by overweight/obesity in major depressive disorder. <i>Journal of Affective Disorders</i> , 2019, 256, 221-227.	2.0	16
178	Antipsychotic use is inversely associated with gastric cancer risk: A nationwide populationâ€•based nested caseâ€•control study. <i>Cancer Medicine</i> , 2019, 8, 4484-4496.	1.3	10
179	Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression. <i>JAMA Psychiatry</i> , 2019, 76, 783.	6.0	135
180	Stress, epigenetics and depression: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 102, 139-152.	2.9	246

#	ARTICLE	IF	CITATIONS
181	Consumer Warning for Genetic Tests Claiming to Predict Response to Medications: Implications for Psychiatry. <i>American Journal of Psychiatry</i> , 2019, 176, 412-413.	4.0	1
182	Prevalence of Burnout in Medical and Surgical Residents: A Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1479.	1.2	210
183	Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy. <i>Journal of Affective Disorders</i> , 2019, 253, 154-161.	2.0	19
184	Aberrant brain structural-functional connectivity coupling in euthymic bipolar disorder. <i>Human Brain Mapping</i> , 2019, 40, 3452-3463.	1.9	40
185	Parental characteristics and the risk of schizophrenia in a Chinese population: a case-control study. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 90-95.	0.7	6
186	Advances and challenges in development of precision psychiatry through clinical metabolomics on mood and psychotic disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 93, 182-188.	2.5	23
187	Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. <i>American Journal of Psychiatry</i> , 2019, 176, 439-448.	4.0	85
188	The relationship between smartphone addiction and symptoms of depression, anxiety, and attention-deficit/hyperactivity in South Korean adolescents. <i>Annals of General Psychiatry</i> , 2019, 18, 1.	1.2	125
189	Does obesity and diabetes mellitus metastasize to the brain? -Metaboptosis-and implications for drug discovery and development. <i>CNS Spectrums</i> , 2019, 24, 467-469.	0.7	5
190	Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed?. <i>Journal of Psychiatric Research</i> , 2019, 114, 208-209.	1.5	8
191	The neural systems of emotion regulation and abnormalities in major depressive disorder. <i>Behavioural Brain Research</i> , 2019, 367, 181-188.	1.2	70
192	The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 17.	1.3	64
193	A clinical model for identifying an inflammatory phenotype in mood disorders. <i>Journal of Psychiatric Research</i> , 2019, 113, 148-158.	1.5	16
194	The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 387-404.	2.5	51
195	Cariprazine for the treatment of bipolar depression: a review. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 317-323.	1.4	13
196	Global Lifetime and 12-Month Prevalence of Suicidal Behavior, Deliberate Self-Harm and Non-Suicidal Self-Injury in Children and Adolescents between 1989 and 2018: A Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4581.	1.2	250
197	Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 100-108.	1.0	20
198	Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 1-7.	2.5	30

#	ARTICLE	IF	CITATIONS
199	Hypersomnia and Bipolar Disorder: A systematic review and meta-analysis of proportion. <i>Journal of Affective Disorders</i> , 2019, 246, 659-666.	2.0	20
200	The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. <i>Journal of Affective Disorders</i> , 2019, 246, 217-223.	2.0	7
201	The long-term effect of bariatric surgery on depression and anxiety. <i>Journal of Affective Disorders</i> , 2019, 246, 886-894.	2.0	117
202	Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 113-119.	1.9	20
203	The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. <i>European Neuropsychopharmacology</i> , 2019, 29, 137-146.	0.3	19
204	New use for old drugs: The protective effect of atypical antipsychotics on hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 2428-2439.	2.3	8
205	Cognitive impairment in major depressive disorder. <i>CNS Spectrums</i> , 2019, 24, 22-29.	0.7	125
206	Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings. <i>Journal of Affective Disorders</i> , 2019, 245, 508-516.	2.0	7
207	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019, 24, 154-162.	0.7	18
208	A pilot case-control study on the association between N-acetyl derivatives in serum and first-episode schizophrenia. <i>Psychiatry Research</i> , 2019, 272, 36-41.	1.7	8
209	Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 109-117.	2.5	93
210	Possible association between social cognition and metabolic dysfunctions in Bipolar Disorder and Schizophrenia: Preliminary results. <i>Journal of Affective Disorders</i> , 2019, 246, 828-835.	2.0	12
211	Neurocognitive and neuroimaging correlates of obesity and components of metabolic syndrome in bipolar disorder: a systematic review. <i>Psychological Medicine</i> , 2019, 49, 738-749.	2.7	46
212	Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 651-662.	1.3	31
213	Cognition in psychiatry: population health, clinical, and research implications. <i>CNS Spectrums</i> , 2019, 24, 2-3.	0.7	0
214	Comparison of serum essential trace metals between patients with schizophrenia and healthy controls. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 51, 79-85.	1.5	32
215	Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2019, 243, 116-120.	2.0	56
216	Oligopeptidases activity in bipolar disorder: Ndel1 and angiotensin I converting enzyme. <i>Journal of Affective Disorders</i> , 2019, 244, 67-70.	2.0	10

#	ARTICLE	IF	CITATIONS
217	Efficacy of vortioxetine in working patients with generalized anxiety disorder. <i>CNS Spectrums</i> , 2019, 24, 249-257.	0.7	9
218	Antidepressant Prescription and Risk of Lung Cancer: A Nationwide Case-Control Study. <i>Pharmacopsychiatry</i> , 2019, 52, 134-141.	1.7	2
219	Risk of Dementia Among Individuals With Psoriasis. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	22
220	Oral Ketamine for Depression. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	76
221	Differential Diagnosis of Major Depressive Disorder Versus Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	9
222	Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	2
223	Getting to Remission. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	1
224	The relationship of depression with the level of blood pressure in population-based Kangbuk Samsung Health Study. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 356-363.	2.3	5
225	Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?. <i>Neuropharmacology</i> , 2018, 136, 335-342.	2.0	20
226	The impact of body mass index in gene expression of reelin pathway mediators in individuals with schizophrenia and mood disorders: A post-mortem study. <i>Journal of Psychiatric Research</i> , 2018, 102, 186-191.	1.5	5
227	Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 475-482.	1.5	12
228	The relationship between inflammatory state and quantity of affective episodes in bipolar disorder. <i>Psychoneuroendocrinology</i> , 2018, 90, 61-67.	1.3	35
229	Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. <i>Bipolar Disorders</i> , 2018, 20, 184-194.	1.1	134
230	The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series. <i>Perspectives in Psychiatric Care</i> , 2018, 54, 507-513.	0.9	9
231	Increased Incidence of Obstructive Sleep Apnea in Hospitalized Children After Enterovirus Infection: A Nationwide Population-based Cohort Study. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 872-879.	1.1	6
232	Effectiveness of a Type 2 Diabetes Screening Intervention in the Canadian Workplace. <i>Canadian Journal of Diabetes</i> , 2018, 42, 493-499.e1.	0.4	6
233	Targeting cytokines in reduction of depressive symptoms: A comprehensive review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 83, 86-91.	2.5	54
234	Association between enterovirus infection and speech and language impairments: A nationwide population-based study. <i>Research in Developmental Disabilities</i> , 2018, 77, 76-86.	1.2	6

#	ARTICLE	IF	CITATIONS
235	Are Antidepressants Harmful in the "General Population"? <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 179-179.	4.0	1
236	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 97-170.	1.1	1,079
237	Depressive disorders: Processes leading to neurogeneration and potential novel treatments. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 189-204.	2.5	37
238	A computational algorithm for personalized medicine in schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 131-136.	1.1	17
239	<scp>SSRIs</scp> associated with decreased risk of hepatocellular carcinoma: A population-based case-control study. <i>Psycho-Oncology</i> , 2018, 27, 187-192.	1.0	33
240	The differential association between history of childhood sexual abuse and body mass index in early and late stages of bipolar disorder. <i>Journal of Affective Disorders</i> , 2018, 227, 214-218.	2.0	17
241	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 128-144.	1.0	68
242	Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. <i>Journal of Affective Disorders</i> , 2018, 227, 219-225.	2.0	135
243	Drug-drug interactions as a result of co-administering δ^9 -THC and CBD with other psychotropic agents. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 51-54.	1.0	64
244	Cognitive Impairment Mediates Workplace Impairment in Adults With Type 2 Diabetes Mellitus: Results From the Motivaction Study. <i>Canadian Journal of Diabetes</i> , 2018, 42, 289-295.	0.4	19
245	Sex differences in the mediators of functional disability in Major Depressive Disorder. <i>Journal of Psychiatric Research</i> , 2018, 96, 108-114.	1.5	14
246	Food addiction: Prevalence, psychopathological correlates and associations with quality of life in a large sample. <i>Journal of Psychiatric Research</i> , 2018, 96, 145-152.	1.5	115
247	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	1.3	32
248	Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2018, 226, 294-300.	2.0	7
249	Obesity and frontal-striatal brain structures in offspring of individuals with bipolar disorder: Results from the global mood and brain science initiative. <i>Bipolar Disorders</i> , 2018, 20, 42-48.	1.1	14
250	Risks of road injuries in patients with bipolar disorder and associations with drug treatments: A population-based matched cohort study. <i>Journal of Affective Disorders</i> , 2018, 226, 124-131.	2.0	5
251	Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 279-288.	2.8	20
252	Gluten related illnesses and severe mental disorders: a comprehensive review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 368-375.	2.9	21

#	ARTICLE	IF	CITATIONS
253	Correlation between brain circuit segregation and obesity. Behavioural Brain Research, 2018, 337, 218-227.	1.2	34
254	Sleep Duration and Quality as Related to Left Ventricular Structure and Function. Psychosomatic Medicine, 2018, 80, 78-86.	1.3	8
255	Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. Journal of Affective Disorders, 2018, 227, 406-415.	2.0	91
256	Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. Journal of Affective Disorders, 2018, 227, 787-794.	2.0	31
257	Prostate cancer and antidepressants: A nationwide population-based nested case-control study. Journal of Affective Disorders, 2018, 227, 834-839.	2.0	4
258	Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study. Research in Developmental Disabilities, 2018, 72, 96-105.	1.2	44
259	Association Between Sleep Duration, Quality and Body Mass Index in the Korean Population. Journal of Clinical Sleep Medicine, 2018, 14, 1353-1360.	1.4	26
260	A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults. Journal of Clinical Psychopharmacology, 2018, 38, 336-343.	0.7	0
261	Liraglutide Activates mTORC1 Signaling and AMPA Receptors in Rat Hippocampal Neurons Under Toxic Conditions. Frontiers in Neuroscience, 2018, 12, 756.	1.4	17
262	Is obesity changing the phenotype of bipolar disorder from predominately euphoric toward mixed presentations?. Bipolar Disorders, 2018, 20, 685-686.	1.1	6
263	Expression of dopamine signaling genes in the post-mortem brain of individuals with mental illnesses is moderated by body mass index and mediated by insulin signaling genes. Journal of Psychiatric Research, 2018, 107, 128-135.	1.5	17
264	Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder. CNS and Neurological Disorders - Drug Targets, 2018, 16, 891-899.	0.8	18
265	Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 655.	1.3	150
266	Brain structural networks and connectomes: the brain–obesity interface and its impact on mental health. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 3199-3208.	1.0	25
267	Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Therapeutic Advances in Psychopharmacology, 2018, 8, 337-348.	1.2	50
268	Factors Associated with the Risk of Developing Coronary Artery Disease in Medicated Patients with Major Depressive Disorder. International Journal of Environmental Research and Public Health, 2018, 15, 2073.	1.2	36
269	Letter to the editor: Inadequate evidence to support improved patient outcomes with combinatorial pharmacogenomics. Journal of Psychiatric Research, 2018, 107, 136-137.	1.5	1
270	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	1.3	18

#	ARTICLE	IF	CITATIONS
271	Prevalence of Depression among Migrants: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2018, 15, 1986.	1.2	75
272	Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sciences, 2018, 210, 177-184.	2.0	61
273	Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive Disorder. Harvard Review of Psychiatry, 2018, 26, 241-249.	0.9	17
274	Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. Neuroscience Letters, 2018, 686, 10-16.	1.0	70
275	Antidepressant medication use and nasopharyngeal cancer risk: a nationwide population-based study. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1101-1106.	1.0	4
276	The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats. Pharmacological Reports, 2018, 70, 1173-1179.	1.5	2
277	Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. Amino Acids, 2018, 50, 1013-1023.	1.2	36
278	Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 95-101.	2.5	34
279	Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2467-2471.	2.2	76
280	Mental Disorders, Antidepressants, and Type 2 Diabetes. JAMA Pediatrics, 2018, 172, 703.	3.3	2
281	Inflammation and Depression in Patients With Autoimmune Disease, Diabetes, and Obesity. , 2018, , 377-392.		2
282	Inflammation in Bipolar Disorder. , 2018, , 445-454.		3
283	Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Brain Research Bulletin, 2018, 142, 1-7.	1.4	70
284	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neuroscience and Biobehavioral Reviews, 2018, 94, 11-16.	2.9	102
285	Predicting antidepressant response using early changes in cognition: A systematic review. Behavioural Brain Research, 2018, 353, 154-160.	1.2	28
286	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. International Journal of Environmental Research and Public Health, 2018, 15, 771.	1.2	80
287	Effects of Antipsychotic Drugs on the Epigenetic Modification of Brain-Derived Neurotrophic Factor Gene Expression in the Hippocampus of Chronic Restraint Stress Rats. Neural Plasticity, 2018, 2018, 1-10.	1.0	19
288	Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. Brain, Behavior, and Immunity, 2018, 73, 115-124.	2.0	90

#	ARTICLE	IF	CITATIONS
289	Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review. <i>Journal of Affective Disorders</i> , 2018, 241, 519-532.	2.0	179
290	IL-1 β , IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer's disease: Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2018, 8, 12050.	1.6	371
291	Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1941-1952.	1.0	5
292	Effects of olanzapine and haloperidol on mTORC1 signaling, dendritic outgrowth, and synaptic proteins in rat primary hippocampal neurons under toxic conditions. <i>Neuroscience Letters</i> , 2018, 686, 59-66.	1.0	4
293	The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2018, 241, 484-491.	2.0	94
294	Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, e1736.	1.1	27
295	Differentiating Medicated Patients Suffering from Major Depressive Disorder from Healthy Controls by Spot Urine Measurement of Monoamines and Steroid Hormones. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 865.	1.2	22
296	The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1789.	1.2	72
297	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2018, 238, 228-232.	2.0	11
298	Leptin and adiponectin levels in major depressive disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2018, 238, 101-110.	2.0	59
299	Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysis. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 258-266.	1.8	11
300	Gaming-addicted teens identify more with their cyber-self than their own self: Neural evidence. <i>Psychiatry Research - Neuroimaging</i> , 2018, 279, 51-59.	0.9	20
301	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. <i>Reviews in the Neurosciences</i> , 2018, 30, 1-7.	1.4	35
302	Rethinking the spectrum of mood disorders: implications for diagnosis and management – Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 1-16.	1.2	6
303	Coronary calcium score as an expression of multisystemic progression of bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2018, 40, 459-460.	0.9	2
304	Arabic Translation, Validation and Cultural Adaptation of the 7-Item Hamilton Depression Rating Scale in Two Community Samples. <i>Sultan Qaboos University Medical Journal</i> , 2018, 18, 167.	0.3	13
305	Association Between Bone Mineral Density and Depressive Symptoms in a Population-Based Sample. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	10
306	Randomized Controlled Trials of Psychoeducation Modalities in the Management of Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	29

#	ARTICLE	IF	CITATIONS
307	Factors That Impact Treatment Decisions. primary care companion for CNS disorders, The, 2018, 20, .	0.2	7
308	Is binge eating a cognitive disorder? Results from the International Mood Disorders Collaborative Project. Annals of Clinical Psychiatry, 2018, 30, 25-31.	0.6	5
309	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Annals of Clinical Psychiatry, 2018, 30, 38-50.	0.6	28
310	Frequency of use and perceived helpfulness of wellness strategies for bipolar and unipolar depression. Annals of Clinical Psychiatry, 2018, 30, 296-304.	0.6	7
311	Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. World Journal of Biological Psychiatry, 2017, 18, 410-423.	1.3	29
312	Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). Scandinavian Journal of Pain, 2017, 15, 62-67.	0.5	11
313	Evidence for Neurocognitive Improvement After Bariatric Surgery: A Systematic Review. Psychosomatics, 2017, 58, 217-227.	2.5	47
314	Guidelines for the recognition and management of mixed depression. CNS Spectrums, 2017, 22, 203-219.	0.7	97
315	Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia. Human Psychopharmacology, 2017, 32, e2585.	0.7	1
316	Adverse effects of obesity on cognitive functions in individuals at ultra high risk for bipolar disorder: Results from the global mood and brain science initiative. Bipolar Disorders, 2017, 19, 128-134.	1.1	28
317	Cannabidiol in medical marijuana: Research vistas and potential opportunities. Pharmacological Research, 2017, 121, 213-218.	3.1	102
318	Microbiota abnormalities and the therapeutic potential of probiotics in the treatment of mood disorders. Reviews in the Neurosciences, 2017, 28, 739-749.	1.4	34
319	Plasma copeptin and metabolic dysfunction in individuals with bipolar disorder. Psychiatry and Clinical Neurosciences, 2017, 71, 624-636.	1.0	12
320	Tryptophan breakdown and cognition in bipolar disorder. Psychoneuroendocrinology, 2017, 81, 144-150.	1.3	42
321	The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects. Expert Opinion on Investigational Drugs, 2017, 26, 767-770.	1.9	14
322	Bipolar disorder and the risk of fracture: A nationwide population-based cohort study. Journal of Affective Disorders, 2017, 218, 246-252.	2.0	23
323	Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments. International Clinical Psychopharmacology, 2017, 32, 72-79.	0.9	10
324	The Efficacy of Psychostimulants in Major Depressive Episodes. Journal of Clinical Psychopharmacology, 2017, 37, 412-418.	0.7	56

#	ARTICLE	IF	CITATIONS
325	A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. <i>Bipolar Disorders</i> , 2017, 19, 198-213.	1.1	39
326	Diagnostic clusters associated with an early onset schizophrenia diagnosis among children and adolescents. <i>Human Psychopharmacology</i> , 2017, 32, e2589.	0.7	13
327	A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 210, 57-65.	2.0	42
328	Major depressive disorder with subthreshold hypomanic (mixed) features: A real-world assessment of treatment patterns and economic burden. <i>Journal of Affective Disorders</i> , 2017, 210, 332-337.	2.0	21
329	Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. <i>CNS Spectrums</i> , 2017, 22, 333-341.	0.7	24
330	Treatment of mixed features in bipolar disorder. <i>CNS Spectrums</i> , 2017, 22, 141-146.	0.7	14
331	Sirukumab: A Potential Treatment for Mood Disorders?. <i>Advances in Therapy</i> , 2017, 34, 78-90.	1.3	44
332	Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems. <i>Journal of Affective Disorders</i> , 2017, 211, 99-106.	2.0	87
333	<sc>BDNF</sc> and <sc>BMI</sc> effects on brain structures of bipolar offspring: results from the global mood and brain science initiative. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 607-614.	2.2	16
334	Digital revolution in depression: A technologies update for clinicians. <i>Personalized Medicine in Psychiatry</i> , 2017, 4-6, 1-6.	0.1	10
335	Air pollution, aeroallergens and suicidality: a review of the effects of air pollution and aeroallergens on suicidal behavior and an exploration of possible mechanisms. <i>Reviews on Environmental Health</i> , 2017, 32, 343-359.	1.1	15
336	Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. <i>Bipolar Disorders</i> , 2017, 19, 614-626.	1.1	155
337	Mixed features and mixed states in psychiatry: from calculus to geometry. <i>CNS Spectrums</i> , 2017, 22, 116-117.	0.7	9
338	Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. <i>European Neuropsychopharmacology</i> , 2017, 27, 1153-1162.	0.3	49
339	Reply to Comments by Drs Glue and Menkes. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 384-385.	0.7	0
340	Efficacy of levomilnacipran extended release in treating major depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 2017-2024.	0.9	5
341	Subthreshold hypomania affects half of patients with bipolar disorder presenting with depressive symptoms. <i>Evidence-Based Mental Health</i> , 2017, 20, e14-e14.	2.2	1
342	U-shaped relationship between depression and body mass index in the Korean adults. <i>European Psychiatry</i> , 2017, 45, 72-80.	0.1	33

#	ARTICLE	IF	CITATIONS
343	Sudden unexpected death in bipolar disorder. <i>Journal of Affective Disorders</i> , 2017, 223, 8-9.	2.0	2
344	Factors affecting lumbar surgery outcome: A nation-wide, population-based retrospective study. <i>Journal of Affective Disorders</i> , 2017, 222, 98-102.	2.0	4
345	Online distribution channel increases article usage on Mendeley: a randomized controlled trial. <i>Scientometrics</i> , 2017, 112, 1537-1556.	1.6	16
346	Effects of escitalopram and paroxetine on mTORC1 signaling in the rat hippocampus under chronic restraint stress. <i>BMC Neuroscience</i> , 2017, 18, 39.	0.8	23
347	The Bipolar Illness Onset study: research protocol for the BIO cohort study. <i>BMJ Open</i> , 2017, 7, e015462.	0.8	119
348	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 222, 14-20.	2.0	39
349	Selfish brain and selfish immune system interplay: A theoretical framework for metabolic comorbidities of mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 72, 43-49.	2.9	25
350	The association between insulin resistance and depression in the Korean general population. <i>Journal of Affective Disorders</i> , 2017, 208, 553-559.	2.0	44
351	The interface of depression and obesity. <i>Obesity Research and Clinical Practice</i> , 2017, 11, 1-10.	0.8	189
352	Personalized medicine in psychiatry. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 12-19.	0.7	46
353	Antidepressants and colorectal cancer: A population-based nested case-control study. <i>Journal of Affective Disorders</i> , 2017, 207, 353-358.	2.0	21
354	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. <i>Journal of Affective Disorders</i> , 2017, 207, 114-120.	2.0	110
355	Treatment recommendations for DSM-5â€“defined mixed features. <i>CNS Spectrums</i> , 2017, 22, 147-154.	0.7	13
356	Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 31-46.	4.0	176
357	A review of the neurobiology of obesity and the available pharmacotherapies. <i>CNS Spectrums</i> , 2017, 22, 29-38.	0.7	17
358	Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1383-1394.	1.1	123
359	Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications. <i>Brain Sciences</i> , 2017, 7, 144.	1.1	162
360	The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2913-2919.	1.0	17

#	ARTICLE	IF	CITATIONS
361	Effects of selective serotonin reuptake inhibitors on glaucoma: A nationwide population-based study. PLoS ONE, 2017, 12, e0173005.	1.1	13
362	The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan. PLoS ONE, 2017, 12, e0173762.	1.1	37
363	Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. International Journal of Bipolar Disorders, 2017, 5, 36.	0.8	15
364	Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study. Clinical Psychopharmacology and Neuroscience, 2017, 15, 391-401.	0.9	2
365	Asthma, corticosteroid use and schizophrenia: A nationwide population-based study in Taiwan. PLoS ONE, 2017, 12, e0173063.	1.1	18
366	Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression. PLoS ONE, 2017, 12, e0186700.	1.1	135
367	Impact of inequalities in health care on the mortality risk of individuals with severe mental illnesses. Revista Brasileira De Psiquiatria, 2017, 39, 193-194.	0.9	4
368	Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget, 2017, 8, 30464-30470.	0.8	22
369	Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD. Current Pharmaceutical Design, 2017, 23, 2065-2072.	0.9	27
370	Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder?. Journal of Clinical Psychiatry, 2017, 78, 720-729.	1.1	115
371	Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. Journal of Clinical Psychiatry, 2017, 78, 703-713.	1.1	46
372	Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2017, 78, 115-121.	1.1	73
373	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction. Journal of Clinical Psychiatry, 2017, 78, 873-881.	1.1	100
374	Assessment of brain functional connectome alternations and correlation with depression and anxiety in major depressive disorders. PeerJ, 2017, 5, e3147.	0.9	25
375	Available Tools for Assessing Cognitive Impairment in Major Depressive Disorder. Journal of Clinical Psychiatry, 2017, 78, e1427.	1.1	0
376	Implementing Treatment Strategies for Different Types of Depression. Journal of Clinical Psychiatry, 2016, 77, 9-15.	1.1	7
377	The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms. Current Molecular Medicine, 2016, 16, 187-205.	0.6	13
378	Editorial (Thematic Issue: Mood Disorders and General Medical Comorbidities: Shared Biology and) Tj ETQq0 0 0 rgBT /Overlogk 10 Tf 50	0.6	0

#	ARTICLE	IF	CITATIONS
379	Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 1-16.	0.9	127
380	Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2016, 17, 80.	1.8	68
381	Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications. <i>Current Molecular Medicine</i> , 2016, 16, 206-215.	0.6	46
382	Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms. <i>Current Molecular Medicine</i> , 2016, 16, 165-178.	0.6	27
383	Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology. <i>Current Molecular Medicine</i> , 2016, 16, 119-136.	0.6	22
384	Bipolar disorders, type 2 diabetes mellitus, and the brain. <i>Current Opinion in Psychiatry</i> , 2016, 29, 1-6.	3.1	25
385	Pharmacologic implications of inflammatory comorbidity in bipolar disorder. <i>Current Opinion in Pharmacology</i> , 2016, 29, 63-69.	1.7	21
386	An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2016, 31, 134-146.	0.9	16
387	Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. <i>Bipolar Disorders</i> , 2016, 18, 373-378.	1.1	20
388	TrendMD: Helping scholarly content providers reach larger and more targeted audiences. <i>Learned Publishing</i> , 2016, 29, 125-129.	0.8	5
389	Extracellular matrix proteins matrix metalloproteinase 9 (MMP9) and soluble intercellular adhesion molecule 1 (sICAM1) and correlations with clinical staging in euthymic bipolar disorder. <i>Bipolar Disorders</i> , 2016, 18, 155-163.	1.1	26
390	Association of Tic Disorders and Enterovirus Infection. <i>Medicine (United States)</i> , 2016, 95, e3347.	0.4	22
391	Cognition in major depressive disorder. <i>Current Opinion in Psychiatry</i> , 2016, 29, 48-55.	3.1	67
392	Assessment of abnormal brain structures and networks in major depressive disorder using morphometric and connectome analyses. <i>Journal of Affective Disorders</i> , 2016, 205, 103-111.	2.0	40
393	Assessing and measuring cognitive function in major depressive disorder. <i>Evidence-Based Mental Health</i> , 2016, 19, 106-109.	2.2	26
394	The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. <i>CNS Spectrums</i> , 2016, 21, 385-392.	0.7	9
395	Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. <i>CNS Spectrums</i> , 2016, 21, 362-366.	0.7	31
396	The 'WikiGuidelines' smartphone application: Bridging the gaps in availability of evidence-based smartphone mental health applications. <i>Technology and Health Care</i> , 2016, 24, 587-590.	0.5	10

#	ARTICLE	IF	CITATIONS
397	A pragmatic approach to the diagnosis and treatment of mixed features in adults with mood disorders. <i>CNS Spectrums</i> , 2016, 21, 25-33.	0.7	11
398	5.44 BODY WEIGHT DID NOT INFLUENCE ASENAPINE EFFICACY IN PEDIATRIC PATIENTS WITH BIPOLAR I DISORDER. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S197-S198.	0.3	1
399	Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorder. <i>BMC Research Notes</i> , 2016, 9, 340.	0.6	27
400	Admixture analysis of age at onset in first episode bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 201, 88-94.	2.0	14
401	Brexipiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. <i>Journal of Affective Disorders</i> , 2016, 201, 116-123.	2.0	27
402	Tianeptine induces mTORC1 activation in rat hippocampal neurons under toxic conditions. <i>Psychopharmacology</i> , 2016, 233, 2617-2627.	1.5	8
403	Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. <i>Journal of Affective Disorders</i> , 2016, 206, 151-160.	2.0	15
404	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 540-560.	0.9	746
405	Interrelation between brain-derived neurotrophic factor and antioxidant enzymes in bipolar disorder. <i>Bipolar Disorders</i> , 2016, 18, 433-439.	1.1	11
406	Selection of cognitive tests for trials of therapeutic agents. <i>Lancet Psychiatry</i> , 2016, 3, 499.	3.7	13
407	Endometrial cancer and antidepressants. <i>Medicine (United States)</i> , 2016, 95, e4178.	0.4	11
408	Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea (the CRESCEND) <i>Trends in Psychiatry and Behavioral Science</i> , 2016, 1, 50-55.	0.4	11
409	Association of serum interleukin-6 with mental health problems in children exposed to perinatal complications and social disadvantage. <i>Psychoneuroendocrinology</i> , 2016, 71, 94-101.	1.3	7
410	Bipolar disorder course, impaired glucose metabolism and antioxidant enzymes activities: A preliminary report. <i>Journal of Psychiatric Research</i> , 2016, 80, 38-44.	1.5	14
411	Sleep and Inflammation: Implications for Domain Approach and Treatment Opportunities. <i>Biological Psychiatry</i> , 2016, 80, 9-11.	0.7	7
412	The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw055.	1.0	141
413	A New Perspective on the Anti-Suicide Effects With Ketamine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 50-56.	0.7	60
414	Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2016, 18, 89-101.	1.1	153

#	ARTICLE	IF	CITATIONS
415	Adipokines, metabolic dysfunction and illness course in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2016, 74, 63-69.	1.5	40
416	Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. <i>Obesity Research and Clinical Practice</i> , 2016, 10, 531-543.	0.8	20
417	Impaired glucose metabolism moderates the course of illness in bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 195, 57-62.	2.0	30
418	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 148-166.	2.9	97
419	Bipolar Disorder and Inflammation. <i>Psychiatric Clinics of North America</i> , 2016, 39, 125-137.	0.7	125
420	The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 153-159.	1.1	35
421	Shared and divergent neurocognitive impairments in adult patients with schizophrenia and bipolar disorder: Whither the evidence?. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 61, 66-89.	2.9	40
422	Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. <i>Current Medical Research and Opinion</i> , 2016, 32, 587-599.	0.9	5
423	Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. <i>Journal of Affective Disorders</i> , 2016, 190, 103-110.	2.0	29
424	Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 535-546.	1.3	51
425	The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv082.	1.0	174
426	Socioeconomic Disadvantage Moderates the Association between Peripheral Biomarkers and Childhood Psychopathology. <i>PLoS ONE</i> , 2016, 11, e0160455.	1.1	14
427	Repurposing of Anti-Diabetic Agents for the Treatment of Cognitive Impairment and Mood Disorders. <i>Current Molecular Medicine</i> , 2016, 16, 465-473.	0.6	9
428	Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 381-389.	0.8	20
429	Depression, Diabetes and Dementia. <i>Key Issues in Mental Health</i> , 2015, , 42-53.	0.6	1
430	Treating to target in major depressive disorder: response to remission to functional recovery. <i>CNS Spectrums</i> , 2015, 20, 17-31.	0.7	38
431	Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 706-710.	0.7	10
432	Invasive Cervical Cancer and Antidepressants. <i>Medicine (United States)</i> , 2015, 94, e1866.	0.4	9

#	ARTICLE	IF	CITATIONS
433	Depression and Employment Status in Primary and Tertiary Care Settings. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 14-22.	0.9	59
434	The Involvement of TNF- α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. <i>Current Neuropharmacology</i> , 2015, 13, 558-576.	1.4	110
435	Autonomic Dysfunction and Depression: A Biomarker of MDD Across the Life Span. <i>Current Psychiatry Reviews</i> , 2015, 11, 1-7.	0.9	5
436	Antidepressants and Gastric Cancer: A Nationwide Population-Based Nested Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0143668.	1.1	20
437	Religious coping and its influence on psychological distress, medication adherence, and quality of life in inflammatory bowel disease. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 219-227.	0.9	38
438	Autobiographical Memory Disturbances in Depression: A Novel Therapeutic Target?. <i>Neural Plasticity</i> , 2015, 2015, 1-14.	1.0	65
439	Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2015, 13, 636-655.	1.4	50
440	Editorial (Thematic Issue: Translational Perspectives in Treatment-Resistant Mood Disorders). <i>Current Neuropharmacology</i> , 2015, 13, 556-557.	1.4	0
441	Treatment Implications of Predominant Polarity and the Polarity Index: A Comprehensive Review. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu079-pyu079.	1.0	34
442	The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder. <i>CNS Drugs</i> , 2015, 29, 577-589.	2.7	113
443	Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 52, 89-104.	2.9	238
444	Novel investigational drugs targeting IL-6 signaling for the treatment of depression. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 459-475.	1.9	41
445	Cognitive Dysfunction in Depression " Pathophysiology and Novel Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1819-1835.	0.8	82
446	Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2015, 62, 18-26.	1.3	70
447	Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1291-1304.	1.0	60
448	Causes of decreased life expectancy over the life span in bipolar disorder. <i>Journal of Affective Disorders</i> , 2015, 180, 142-147.	2.0	139
449	Body fat distribution and associations with metabolic and clinical characteristics in bipolar individuals. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 313-319.	1.8	23
450	Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study. <i>Advances in Therapy</i> , 2015, 32, 429-444.	1.3	20

#	ARTICLE	IF	CITATIONS
451	The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 101-114.	1.2	6
452	Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 180-191.	2.2	84
453	Correlates of benzodiazepine use in major depressive disorder: The effect of anhedonia. <i>Journal of Affective Disorders</i> , 2015, 187, 101-105.	2.0	19
454	Prevalence of fibromyalgia and co-morbid bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2015, 188, 134-142.	2.0	27
455	Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. <i>Journal of Affective Disorders</i> , 2015, 188, 149-159.	2.0	126
456	Evidence to support peripheral and central IL-6 signaling targets to treat depression. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 991-992.	1.9	1
457	Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease. <i>Circulation</i> , 2015, 132, 965-986.	1.6	371
458	P2.f.018 Effect of adjunctive brexpiprazole (OPC-34712) on depressive symptoms in patients with symptoms of anxious distress: results from post-hoc analyses. <i>European Neuropsychopharmacology</i> , 2015, 25, S444-S445.	0.3	1
459	The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project. <i>Comprehensive Psychiatry</i> , 2015, 56, 279-282.	1.5	123
460	Sex Hormone Binding Globulin and Verbal Memory in Older Men. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 253-260.	0.6	14
461	Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder—Gender and obesity effects. <i>Journal of Affective Disorders</i> , 2015, 172, 367-374.	2.0	50
462	Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. <i>Journal of Affective Disorders</i> , 2015, 172, 337-346.	2.0	75
463	The prevalence and illness characteristics of DSM-5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. <i>Journal of Affective Disorders</i> , 2015, 172, 259-264.	2.0	96
464	Weight cycling in bipolar disorder. <i>Journal of Affective Disorders</i> , 2015, 171, 33-38.	2.0	32
465	Risk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorder. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 65-73.	2.8	25
466	Cerebral White Matter Lesions and Affective Episodes Correlate in Male Individuals with Bipolar Disorder. <i>PLoS ONE</i> , 2015, 10, e0135313.	1.1	17
467	From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings. <i>Current Neuropharmacology</i> , 2015, 13, 605-615.	1.4	11
468	Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1804-1818.	0.8	151

#	ARTICLE	IF	CITATIONS
469	Towards a "Metabolic" Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1693-1707.	0.8	46
470	Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1667-1676.	0.8	5
471	Major Depressive Disorder and Type II Diabetes Mellitus: Mechanisms Underlying Risk for Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1740-1749.	0.8	10
472	The Putative Impact of Metabolic Health on Default Mode Network Activity and Functional Connectivity in Neuropsychiatric Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1750-1758.	0.8	13
473	Gut Emotions - Mechanisms of Action of Probiotics as Novel Therapeutic Targets for Depression and Anxiety Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1770-1786.	0.8	52
474	Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1836-1845.	0.8	25
475	Lurasidone in the Treatment of Bipolar Depression With Mixed (Subsyndromal Hypomanic) Features. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 398-405.	1.1	57
476	Desvenlafaxine for the treatment of major depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1449-1463.	0.9	13
477	Major depressive disorder and cognitive impairment. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, E36-E37.	1.4	5
478	Advancing biomarker research: utilizing "Big Data" approaches for the characterization and prevention of bipolar disorder. <i>Bipolar Disorders</i> , 2014, 16, 531-547.	1.1	57
479	Sex differences in rates of obesity in bipolar disorder: postulated mechanisms. <i>Bipolar Disorders</i> , 2014, 16, 83-92.	1.1	32
480	Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. <i>Bipolar Disorders</i> , 2014, 16, 432-440.	1.1	69
481	Increased body mass index makes an impact on brain white-matter integrity in adults with remitted first-episode mania. <i>Psychological Medicine</i> , 2014, 44, 533-541.	2.7	28
482	The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 70-88.	4.0	93
483	A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1557-1567.	1.0	335
484	Screening for bipolar depression in family medicine practices: Prevalence and clinical correlates. <i>Journal of Affective Disorders</i> , 2014, 162, 120-127.	2.0	7
485	Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. <i>Journal of Affective Disorders</i> , 2014, 156, 1-7.	2.0	337
486	The theory of bipolar disorder as an illness of accelerated aging: Implications for clinical care and research. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 42, 157-169.	2.9	146

#	ARTICLE	IF	CITATIONS
487	Predominant polarity as a course specifier for bipolar disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2014, 163, 56-64.	2.0	74
488	Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression. <i>NeuroImmunoModulation</i> , 2014, 21, 131-139.	0.9	40
489	The mechanism, efficacy, and tolerability profile of agomelatine. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 259-274.	0.9	21
490	Inflamed moods: A review of the interactions between inflammation and mood disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 53, 23-34.	2.5	468
491	Implications of epigenetic modulation for novel treatment approaches in patients with schizophrenia. <i>Neuropharmacology</i> , 2014, 77, 481-486.	2.0	12
492	P.2.b.033 An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. <i>European Neuropsychopharmacology</i> , 2014, 24, S398.	0.3	0
493	Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. <i>Journal of Affective Disorders</i> , 2014, 168, 136-141.	2.0	28
494	Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. <i>Bipolar Disorders</i> , 2014, 16, 451-454.	1.1	7
495	Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2014, 59, 28-37.	1.5	98
496	The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial. <i>Psychiatry Research</i> , 2014, 220, 245-250.	1.7	45
497	A Vision for Drug Discovery and Development: Novel Targets and Multilateral Partnerships. <i>Advances in Therapy</i> , 2014, 31, 245-246.	1.3	23
498	Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions. <i>CNS Drugs</i> , 2014, 28, 601-609.	2.7	72
499	Diabetes Mellitus and Disturbances in Brain Connectivity: A Bidirectional Relationship?. <i>NeuroMolecular Medicine</i> , 2014, 16, 658-668.	1.8	25
500	Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. <i>Journal of Affective Disorders</i> , 2014, 164, 57-62.	2.0	37
501	Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 161, 123-126.	2.0	38
502	Major depressive disorder in breast cancer: A critical systematic review of pharmacological and psychotherapeutic clinical trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 349-355.	3.4	40
503	Metabolic Syndrome and Elevated C-Reactive Protein Levels in Elderly Patients With Newly Diagnosed Depression. <i>Psychosomatics</i> , 2014, 55, 640-649.	2.5	17
504	Psychosocial predictors of health outcomes in colorectal cancer: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2014, 40, 800-809.	3.4	45

#	ARTICLE	IF	CITATIONS
505	Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. <i>CNS Spectrums</i> , 2014, 19, 182-196.	0.7	4
506	Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 649-654.	0.9	276
507	Treatment-Resistant Depression in Primary Care across Canada. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 349-357.	0.9	120
508	Hot™ versus cold™ cognition. , 2014, , 21-30.		1
509	Rapid Cycling in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e578-e586.	1.1	92
510	Correlates of Incident Bipolar Disorder in Children and Adolescents Diagnosed With Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e1278-e1283.	1.1	23
511	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 795-807.	1.4	11
512	COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS. <i>Depression and Anxiety</i> , 2013, 30, 515-527.	2.0	586
513	Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. <i>Journal of Psychiatric Research</i> , 2013, 47, 1521-1529.	1.5	161
514	The Effect of Personality Dimensions on Functional Outcomes in Mood Disorders. <i>Advances in Therapy</i> , 2013, 30, 671-683.	1.3	3
515	Obesity and Mental Illness: Implications for Cognitive Functioning. <i>Advances in Therapy</i> , 2013, 30, 577-588.	1.3	11
516	Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. <i>Sleep Medicine</i> , 2013, 14, 943-949.	0.8	39
517	Selfish brain and neuroprogression in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 43, 66-71.	2.5	22
518	The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. <i>Bipolar Disorders</i> , 2013, 15, 753-763.	1.1	35
519	Obesity and Bipolar Disorder: Synergistic Neurotoxic Effects?. <i>Advances in Therapy</i> , 2013, 30, 987-1006.	1.3	32
520	Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrenergic pathways. <i>Journal of Psychopharmacology</i> , 2013, 27, 1032-1043.	2.0	105
521	The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1161-1182.	1.4	6
522	Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1183-1200.	1.4	6

#	ARTICLE	IF	CITATIONS
523	The impact of obesity on quality of life. Best Practice and Research in Clinical Endocrinology and Metabolism, 2013, 27, 139-146.	2.2	175
524	Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. Journal of Affective Disorders, 2013, 151, 573-581.	2.0	48
525	Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: A pooled, post hoc analysis from the asenapine development program. Journal of Affective Disorders, 2013, 150, 745-752.	2.0	11
526	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.1	740
527	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disorders, 2013, 15, 58-60.	1.1	14
528	Is there a role for curcumin in the treatment of bipolar disorder?. Medical Hypotheses, 2013, 80, 606-612.	0.8	20
529	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. Bipolar Disorders, 2013, 15, 338-339.	1.1	1
530	Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. Journal of Affective Disorders, 2013, 150, 639-643.	2.0	7
531	Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neuroscience and Biobehavioral Reviews, 2013, 37, 911-929.	2.9	91
532	DSM-5 mixed specifier for manic episodes: Evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. Journal of Affective Disorders, 2013, 150, 378-383.	2.0	60
533	The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behavioural Brain Research, 2013, 237, 164-171.	1.2	79
534	The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Human Psychopharmacology, 2013, 28, 421-427.	0.7	22
535	Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: Relevance as an animal model of mania. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 43, 230-237.	2.5	44
536	Acute Effects of Single-Dose Olanzapine on Metabolic, Endocrine, and Inflammatory Markers in Healthy Controls. Journal of Clinical Psychopharmacology, 2013, 33, 740-746.	0.7	67
537	Conceptualising the neurobiology of fatigue. Australian and New Zealand Journal of Psychiatry, 2013, 47, 312-316.	1.3	19
538	Fatigue and occupational functioning in major depressive disorder. Australian and New Zealand Journal of Psychiatry, 2013, 47, 989-991.	1.3	14
539	A review of FDA-approved treatment options in bipolar depression. CNS Spectrums, 2013, 18, 1-21.	0.7	28
540	Cognitive Enhancement in Canadian Medical Students. Journal of Psychoactive Drugs, 2013, 45, 360-365.	1.0	48

#	ARTICLE	IF	CITATIONS
541	Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1755-1765.	1.0	7
542	A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 143.	1.0	19
543	Seasonal and temperamental contributions in patients with bipolar disorder and metabolic syndrome. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 210-210.	0.9	6
544	Using Measurement Strategies to Identify and Monitor Residual Symptoms. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 14-18.	1.1	22
545	Economic Grand Rounds: Economic Costs of Failure to Monitor Adverse Effects of Second-Generation Antipsychotics: An Underestimated Factor. <i>Psychiatric Services</i> , 2012, 63, 202-204.	1.1	9
546	The Association between Childhood Adversity and Components of Metabolic Syndrome in Adults with Mood Disorders: Results from the International Mood Disorders Collaborative Project. <i>International Journal of Psychiatry in Medicine</i> , 2012, 43, 165-177.	0.8	67
547	Understanding the "Concept of Noise" in Mental Health Care Encounters With Patients From Different Cultures. <i>Home Health Care Management and Practice</i> , 2012, 24, 81-87.	0.4	0
548	Predicting Treatment Response in Major Depressive Disorder: The Impact of Early Symptomatic Improvement. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 782-788.	0.9	27
549	Beyond Pharmacotherapy: Understanding the Links between Obesity and Chronic Mental Illness. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 5-12.	0.9	62
550	A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 1-8.	2.5	43
551	Effects of alpha-lipoic acid in an animal model of mania induced by amphetamine. <i>Bipolar Disorders</i> , 2012, 14, 707-718.	1.1	47
552	Novel therapeutic targets in depression: Minocycline as a candidate treatment. <i>Behavioural Brain Research</i> , 2012, 235, 302-317.	1.2	162
553	The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. <i>European Psychiatry</i> , 2012, 27, 223-228.	0.1	96
554	Screening for bipolar disorder in the primary care: A Brazilian survey. <i>Journal of Affective Disorders</i> , 2012, 143, 118-124.	2.0	13
555	Foreword. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, i-ii.	0.9	0
556	A review of published evidence reporting on the efficacy and pharmacology of lurasidone. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1653-1659.	0.9	9
557	The neurobiology of the EEG biomarker as a predictor of treatment response in depression. <i>Neuropharmacology</i> , 2012, 63, 507-513.	2.0	148
558	Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine. <i>Medical Hypotheses</i> , 2012, 78, 601-605.	0.8	24

#	ARTICLE	IF	CITATIONS
559	A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. <i>Bipolar Disorders</i> , 2012, 14, 697-706.	1.1	81
560	Admixture analysis of age at onset in major depressive disorder. <i>General Hospital Psychiatry</i> , 2012, 34, 686-691.	1.2	19
561	Treatment-emergent adverse events associated with atypical antipsychotics. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1587-1598.	0.9	54
562	Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. <i>Journal of Affective Disorders</i> , 2012, 140, 82-91.	2.0	85
563	Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. <i>Bipolar Disorders</i> , 2012, 14, 1-21.	1.1	48
564	Efficacy of antimanic treatments in mixed states. <i>Bipolar Disorders</i> , 2012, 14, 22-36.	1.1	34
565	Asenapine: A Synthesis of Efficacy Data in Bipolar Mania and Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 5, 217-220.	1.4	17
566	Crosstalk between metabolic and neuropsychiatric disorders. <i>F1000 Biology Reports</i> , 2012, 4, 14.	4.0	46
567	The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 6-22.	0.6	68
568	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 23-37.	0.6	74
569	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 38-55.	0.6	42
570	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 56-68.	0.6	25
571	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 69-81.	0.6	70
572	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 91-109.	0.6	56
573	Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 163-9.	0.6	58
574	Insulin dysfunction and allostatic load in bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1017-1028.	1.4	54
575	Effects of once-daily adjunct quetiapine XR on sleep disturbance in patients with mdd: a pooled analysis from two acute studies. <i>European Psychiatry</i> , 2011, 26, 608-608.	0.1	0
576	Asenapine: A Review of Acute and Extension Phase Data in Bipolar Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 645-648.	1.9	18

#	ARTICLE	IF	CITATIONS
577	Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 319.	1.0	15
578	Aripiprazole: striving towards euthymia with a novel mechanism of action. <i>Journal of Affective Disorders</i> , 2011, 128, S1-S2.	2.0	2
579	Depression in the workforce: the intermediary effect of medical comorbidity. <i>Journal of Affective Disorders</i> , 2011, 128, S29-S36.	2.0	48
580	Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. <i>Journal of Neural Transmission</i> , 2011, 118, 1621-1639.	1.4	26
581	Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus. <i>NeuroMolecular Medicine</i> , 2011, 13, 93-116.	1.8	135
582	Surgical treatment of morbid obesity among patients with bipolar disorder: a research agenda. <i>Advances in Therapy</i> , 2011, 28, 389-400.	1.3	13
583	Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. <i>Human Psychopharmacology</i> , 2011, 26, 451-459.	0.7	21
584	Transforming drug safety information. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 1-2.	1.0	1
585	Performance Improvement CME: Long-Term Treatment of Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, e09.	1.1	7
586	Long-Term Treatment of Bipolar Disorder in Adults. <i>Journal of Clinical Psychiatry</i> , 2011, 72, e06.	1.1	6
587	Implementing Guideline-Based Strategies to Avoid Relapse and Recurrence in Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, e35.	1.1	0
588	Frequency and Correlates of Gambling Problems in Outpatients with Major Depressive Disorder and Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 568-576.	0.9	44
589	Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: Points of pathophysiological commonality with mood disorders?. <i>Advances in Therapy</i> , 2010, 27, 63-80.	1.3	69
590	The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. <i>Advances in Therapy</i> , 2010, 27, 828-836.	1.3	33
591	Foreword. <i>Clinical Therapeutics</i> , 2010, 32, S1-S2.	1.1	1
592	Aripiprazole for the maintenance treatment of bipolar I disorder: A review. <i>Clinical Therapeutics</i> , 2010, 32, S32-S38.	1.1	24
593	Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Affective Disorders</i> , 2010, 122, 27-38.	2.0	153
594	Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study. <i>Journal of Affective Disorders</i> , 2010, 126, 358-365.	2.0	103

#	ARTICLE	IF	CITATIONS
595	Bipolar disorder and metabolic syndrome: An international perspective. <i>Journal of Affective Disorders</i> , 2010, 126, 366-387.	2.0	177
596	The Relationship between Testosterone and Sexual Function in Depressed and Healthy Men. <i>Journal of Sexual Medicine</i> , 2010, 7, 816-825.	0.3	38
597	Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 744-755.	0.9	23
598	Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. <i>Bipolar Disorders</i> , 2010, 12, 691-701.	1.1	24
599	Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 645-649.	1.4	23
600	Aerobic Physical Exercise as a Possible Treatment for Neurocognitive Dysfunction in Bipolar Disorder. <i>Postgraduate Medicine</i> , 2010, 122, 107-116.	0.9	50
601	Atypical antipsychotic tolerability and switching strategies in bipolar disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2827-2837.	0.9	13
602	The Association between Conventional Antidepressants and the Metabolic Syndrome. <i>CNS Drugs</i> , 2010, 24, 741-753.	2.7	73
603	P.2.a.034 Impact of methodology on the efficacy of extended release quetiapine fumarate in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2010, 20, S353.	0.3	2
604	A Cohort Study of the Prevalence and Impact of Comorbid Medical Conditions in Pediatric Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1518-1525.	1.1	94
605	When Should You Move Beyond First-Line Therapy for Depression?. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 16-20.	1.1	16
606	Attention-Deficit/Hyperactivity Disorder in Adults With Bipolar Disorder or Major Depressive Disorder. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, .	0.6	54
607	Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 3061-3075.	0.9	30
608	Review: non-pharmacological interventions reduce antipsychotic induced weight gain. <i>Evidence-Based Mental Health</i> , 2009, 12, 52-52.	2.2	1
609	Cardiovascular and Neurological Adverse Events Associated With Antidepressant Treatment in Children and Adolescents. <i>Journal of Child Neurology</i> , 2009, 24, 297-304.	0.7	10
610	Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 92, 12-16.	1.3	16
611	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. <i>Journal of Affective Disorders</i> , 2009, 117, S26-S43.	2.0	357
612	Exercise and Bipolar Disorder: A Review of Neurobiological Mediators. <i>NeuroMolecular Medicine</i> , 2009, 11, 328-336.	1.8	41

#	ARTICLE	IF	CITATIONS
613	Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap. <i>Current Diabetes Reports</i> , 2009, 9, 51-59.	1.7	117
614	Teratogenesis associated with antipolar agents. <i>Advances in Therapy</i> , 2009, 26, 281-294.	1.3	49
615	Psychotropic drugs and renal failure: Translating the evidence for clinical practice. <i>Advances in Therapy</i> , 2009, 26, 404-424.	1.3	23
616	Long-acting risperidone: a review of its role in the treatment of bipolar disorder. <i>Advances in Therapy</i> , 2009, 26, 588-599.	1.3	15
617	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. <i>Bipolar Disorders</i> , 2009, 11, 225-255.	1.1	545
618	A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. <i>Bipolar Disorders</i> , 2009, 11, 673-686.	1.1	176
619	Asenapine versus olanzapine in acute mania: a double-blind extension study. <i>Bipolar Disorders</i> , 2009, 11, 815-826.	1.1	105
620	Health-Care Costs of Pediatric Clients Developing Adverse Events during Treatment with Antipsychotics. <i>Value in Health</i> , 2009, 12, 716-722.	0.1	5
621	Discontinued psychiatric drugs in 2008. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1431-1443.	1.9	20
622	The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression?. <i>NeuroToxicology</i> , 2009, 30, 497-521.	1.4	83
623	Bipolar Disorder and ADHD: Clinical Concerns. <i>CNS Spectrums</i> , 2009, 14, 8-9.	0.7	9
624	Polypharmacy in Children and Adolescents Treated for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 240-246.	1.1	51
625	Inflammation and the Phenomenology, Pathophysiology, Comorbidity, and Treatment of Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1078-1090.	1.1	444
626	Balancing the Equation: Managing Comorbidities in Patients With Severe Mental Illness. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 04.	1.1	3
627	Understanding Needs, Interactions, Treatment, and Expectations Among Individuals Affected by Bipolar Disorder or Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 05-11.	1.1	48
628	Correlates of Metabolic Abnormalities in Bipolar I Disorder at Initiation of Acute Phase Treatment. <i>Psychiatry Investigation</i> , 2009, 6, 78.	0.7	25
629	Adverse events in children and adolescents treated with antipsychotic medications. <i>Human Psychopharmacology</i> , 2008, 23, 283-290.	0.7	66
630	Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. <i>Bipolar Disorders</i> , 2008, 10, 1-37.	1.1	245

#	ARTICLE	IF	CITATIONS
631	Varenicline and suicidality: a new era in medication safety surveillance. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 511-514.	1.0	11
632	Insulin, Insulin-Like Growth Factors??and Incretins. <i>CNS Drugs</i> , 2008, 22, 443-453.	2.7	17
633	The Relationship Between Childhood Abuse and Suicidality in Adult Bipolar Disorder. <i>Violence and Victims</i> , 2008, 23, 361-372.	0.4	51
634	The hepatic safety profile of duloxetine: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 281-285.	1.5	47
635	Validity of conclusions about quetiapine. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 114-115.	0.5	0
636	Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents. <i>JAMA Pediatrics</i> , 2008, 162, 929.	3.6	158
637	Recently patented agents with possible antipsychotic indication. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 1327-1332.	2.4	0
638	Acetyl-L-carnitine and α -lipoic acid: possible neurotherapeutic agents for mood disorders?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 827-843.	1.9	18
639	Assessing the Prevalence of Depression among Individuals with Diabetes in a Medicaid Managed-Care Program. <i>International Journal of Psychiatry in Medicine</i> , 2008, 38, 13-29.	0.8	25
640	Considering Wellness in Managing Patients with Bipolar Disorder. <i>CNS Spectrums</i> , 2008, 13, 7-8.	0.7	1
641	Conclusion: Summary and Recommendations. <i>CNS Spectrums</i> , 2008, 13, 13-14.	0.7	6
642	Acute Treatment of Patients With Bipolar Mixed Episodes. <i>Journal of Clinical Psychiatry</i> , 2008, 69, e10.	1.1	2
643	The effect of bipolar I disorder and major depressive disorder on workforce function. <i>Chronic Diseases in Canada</i> , 2008, 28, 84-91.	0.9	7
644	Predictors of symptomatic remission in people with schizophrenia identified. <i>Evidence-Based Mental Health</i> , 2007, 10, 73-73.	2.2	0
645	A preclinical and clinical rationale for quetiapine in mood syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1211-1219.	0.9	55
646	Sex Differences in Antidepressant Response in a Canadian Primary-Care Sample. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 95-98.	0.7	4
647	Medical comorbidity in bipolar disorder: reprioritizing unmet needs. <i>Current Opinion in Psychiatry</i> , 2007, 20, 406-416.	3.1	114
648	Thiazolidinediones: From antioxidant to neurotherapeutic?. <i>Medical Hypotheses</i> , 2007, 69, 773-777.	0.8	5

#	ARTICLE	IF	CITATIONS
649	Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?. Expert Opinion on Pharmacotherapy, 2007, 8, 1615-1628.	0.9	28
650	Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"? Annals of Clinical Psychiatry, 2007, 19, 257-264.	0.6	215
651	Predictors of Self-Reported Antidepressant Adherence. Behavioral Medicine, 2007, 32, 127-134.	1.0	76
652	Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opinion on Pharmacotherapy, 2007, 8, 1001-1009.	0.9	27
653	Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Human Psychopharmacology, 2007, 22, 361-364.	0.7	10
654	Measuring depressive symptoms in the naturalistic primary-care setting. International Journal of Clinical Practice, 2007, 61, 1278-1282.	0.8	2
655	Problem gambling in bipolar disorder: Results from the Canadian Community Health Survey. Journal of Affective Disorders, 2007, 102, 27-34.	2.0	46
656	Quetiapine in the treatment of acute bipolar mania: Efficacy across a broad range of symptoms. Journal of Affective Disorders, 2007, 100, S5-S14.	2.0	29
657	Relationship between regional brain metabolism, illness severity and age in depressed subjects. Psychiatry Research - Neuroimaging, 2007, 155, 203-210.	0.9	46
658	Substance Use Disorders and Overweight/Obesity in Bipolar I Disorder. Journal of Clinical Psychiatry, 2007, 68, 1352-1357.	1.1	65
659	Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder. Journal of Clinical Psychiatry, 2007, 68, 1480-1491.	1.1	216
660	The effect of antidepressants on lipid homeostasis: a cardiac safety concern?. Expert Opinion on Drug Safety, 2006, 5, 523-537.	1.0	70
661	Measurable outcomes in psychiatric disorders: Remission as a marker of wellness. Clinical Therapeutics, 2006, 28, 1882-1891.	1.1	42
662	Improving outcomes in depression: A focus on somatic symptoms. Journal of Psychosomatic Research, 2006, 60, 279-282.	1.2	46
663	Obesity in Bipolar Disorder and Major Depressive Disorder: Results from a National Community Health Survey on Mental Health and Well-Being. Canadian Journal of Psychiatry, 2006, 51, 274-280.	0.9	133
664	Anxiety disorders and bipolar disorder: a review. Bipolar Disorders, 2006, 8, 665-676.	1.1	78
665	Comorbidity in bipolar disorder: clinical and research opportunities. Bipolar Disorders, 2006, 8, 645-647.	1.1	13
666	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disorders, 2006, 8, 721-739.	1.1	202

#	ARTICLE	IF	CITATIONS
667	The Prevalence and Impact of Migraine Headache in Bipolar Disorder: Results From the Canadian Community Health Survey.. Headache, 2006, 46, 973-982.	1.8	104
668	Calculated bioavailable testosterone levels and depression in middle-aged men. Psychoneuroendocrinology, 2006, 31, 1029-1035.	1.3	96
669	Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 36-43.	1.1	81
670	One size fits all?. Cmaj, 2006, 174, 1133-1134.	0.9	1
671	Medical Comorbidity in Bipolar Disorder: Implications for Functional Outcomes and Health Service Utilization. Psychiatric Services, 2006, 57, 1140-1144.	1.1	164
672	The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opinion on Drug Safety, 2006, 5, 157-168.	1.0	198
673	Open-Label Adjunctive Topiramate in the Treatment of Unstable Bipolar Disorder. Canadian Journal of Psychiatry, 2005, 50, 415-422.	0.9	29
674	Atypical Antipsychotics in Psychiatric Practice: Practical Implications for Clinical Monitoring. Canadian Journal of Psychiatry, 2005, 50, 555-562.	0.9	30
675	Antidepressant Augmentation With Raloxifene. Journal of Clinical Psychopharmacology, 2005, 25, 96-98.	0.7	11
676	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders, 2005, 7, 5-69.	1.1	321
677	Bipolar Disorder and Diabetes Mellitus: Epidemiology, Etiology, and Treatment Implications. Annals of Clinical Psychiatry, 2005, 17, 83-93.	0.6	188
678	Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. Cmaj, 2005, 173, 1327-1334.	0.9	103
679	Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. Cmaj, 2005, 172, 57-59.	0.9	47
680	Quetiapine or haloperidol as monotherapy for bipolar mania—a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. European Neuropsychopharmacology, 2005, 15, 573-585.	0.3	195
681	Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms. Expert Opinion on Pharmacotherapy, 2005, 6, 707-713.	0.9	10
682	Comorbidity in bipolar disorder: a framework for rational treatment selection. Human Psychopharmacology, 2004, 19, 369-386.	0.7	58
683	Bipolar Disorder: A National Health Concern. CNS Spectrums, 2004, 9, 6-15.	0.7	42
684	Treating bipolar disorder. Evidence-based guidelines for family medicine. Canadian Family Physician, 2004, 50, 388-94.	0.1	9

#	ARTICLE	IF	CITATIONS
685	The human cost of not achieving full remission in depression. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 10S-16S.	0.9	53
686	The antidepressant effects of risperidone and olanzapine in bipolar disorder. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2004, 11, e218-26.	1.9	4
687	Valproate, bipolar disorder and polycystic ovarian syndrome. <i>Bipolar Disorders</i> , 2003, 5, 28-35.	1.1	103
688	The role of atypical antipsychotics in bipolar depression and anxiety disorders. <i>Bipolar Disorders</i> , 2003, 5, 20-35.	1.1	49
689	Antipsychotic-Induced Weight Gain: Bipolar Disorder and Leptin. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 323-327.	0.7	44
690	Risk of Weight Gain Associated with Antipsychotic Treatment: Results from the Canadian National Outcomes Measurement Study in Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 689-694.	0.9	53
691	What to do if an initial antidepressant fails?. <i>Canadian Family Physician</i> , 2003, 49, 449-57.	0.1	13
692	Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. <i>Bipolar Disorders</i> , 2002, 4, 207-213.	1.1	145
693	Combining Bupropion SR With Venlafaxine, Paroxetine, or Fluoxetine. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 181-186.	1.1	117
694	Assessing full remission. <i>Journal of Psychiatry and Neuroscience</i> , 2002, 27, 235-9.	1.4	67
695	Lithium Revisited. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 322-327.	0.9	28
696	Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 273-281.	0.9	224
697	Mechanisms of antipsychotic-induced weight gain. <i>Journal of Clinical Psychiatry</i> , 2001, 62 Suppl 23, 23-9.	1.1	16
698	Do Depressed Subjects Who Have Failed Both Fluoxetine and a Tricyclic Antidepressant Respond to the Combination?. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 613-616.	1.1	27
699	Risperidone Treatment of Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 1997, 42, 88-90.	0.9	16